Quantcast

Latest Tyrosine kinase inhibitors Stories

2010-12-13 21:01:47

Chronic myeloid leukemia (CML) was transformed from a fatal disease to a chronic condition by the development of a drug known as imatinib, which targets the protein that drives this disease (BCR-ABL).

2010-12-09 17:20:06

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer.

2010-12-09 07:45:00

RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs.

2010-12-09 07:45:00

WALTHAM, Mass., Dec. 9, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC).

2010-12-06 12:19:16

A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start.

2010-12-06 12:07:46

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies.

2010-12-03 16:01:00

NEW YORK, Dec. 3, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients.


Word of the Day
definiens
  • The word or words serving to define another word or expression, as in a dictionary entry.
The word 'definiens' comes from the Latin word 'definire', 'to define'.
Related